Mats Wahlstrom, Director at TriSalus Life Sciences, Inc. (TLSI), bought 60,000 shares at $2.53 ($152K) on 2026-05-15, disclosed to the SEC on 2026-05-18.
Director Mats Wahlstrom purchased 60,000 shares at $2.53 on May 15, 2026, marking the largest insider purchase in the company's history. This aggressive buying occurs as the stock has plummeted 34.98% over the last 30 days, potentially signaling a contrarian bet on the company's clinical pipeline.
TLSI has crashed 34.98% over the last 30 days and is currently trading 62.01% below its 52-week high of $7.95.
Catalysts include the delayed FDA review for the TriNav Advance device reported on May 13, 2026, and the initiation of patient enrollment for the PREDICTT liver tumor clinical trial on May 10, 2026. Additionally, the purchase marks the largest insider transaction in the company's history, potentially signaling confidence despite recent revenue misses.
Risks include the company's reduced full-year 2026 revenue outlook due to a commercial reorganization and delayed FDA review for the TriNav Advance device, reported on May 13, 2026. Furthermore, Canaccord lowered the price target to $7 from $12 on March 12, 2026, despite maintaining a Buy rating.
Clearly above the average filing.
| Filing → |
| TLSI | BUY | 2024-11-22 | $47K | — | Filing → |
| CHRS | SELL | 2020-06-19 | $6.9M | — | Filing → |
| CHRS | SELL | 2020-03-05 | $4.8M | — | Filing → |